Trial Profile
Observational, Non-interventional, Multicenter Study Aimed at Collecting Retrospective/Prospective 648/96 Italian Registry Data Related to Lenalidomide (Revlimid) Prescription to Patients With Myelodysplastic Syndromes
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Nov 2019
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Acronyms MORE
- Sponsors Celgene Corporation
- 23 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 04 Jun 2013 Planned End Date changed from 1 Jun 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 08 Aug 2012 Planned End Date changed from 1 Dec 2011 to 1 Jun 2013 as reported by ClinicalTrials.gov.